Long-term outcomes after St. Jude Medical mechanical valve implantation.

patient-year), major bleeding events (1.0%/patient-year), and aortic valve reoperation (0.26%/patient-year). They also reported that valve-related death was the most common cause of death (26.8%) and that the rates of freedom from valve-related death were 96.2%, 92.7%, 88.8%, and 86.6% at 5, 10, 15, and 20 years, respectively. These results compare favorably with the findings of previous reports,1–4 and were mainly affected by control of the prothrombin-international normalized ratio (PTINR). In the Japanese guidelines, the optimal range for PTINR during aortic mechanical valve replacement is 2.0–2.5 (vs. 2.0–3.0 for mitral mechanical valves and atrial fibrillation [AF]).8 Although the PT-INR target was the same as in the Japanese guidelines, the frequency of PT-INR control within the optimal range was not ascertained in this study. Unfortunately, PT-INR tends to drift, which can lead to thromboembolic and bleeding events. Furthermore, for very long periods of warfarin administration, it may be important to quantify the maintenance of the target PT-INR (eg, the time in the therapeutic range for PT-INR, which has been used for AF).9,10 Moreover, the risk of thromboembolic and bleeding events varies according to age, and it is possible that the specific optimal range for PT-INR might vary according to the patient’s age. One complication of mechanical valve use is pannus formation during the follow-up.11 Although many factors are involved (eg, inflammation, thrombus formation, and turbulence around the valve), the precise cause of pannus formation has not been determined.12 Therefore, given that reoperations are rarely performed for mechanical valves, the frequency of pannus formation is very important. In this context, the SJM mechanical he St. Jude Medical (SJM) mechanical valve is a bileaflet valve that is constructed using pyloric carbon to achieve the concept of “one valve in one life.” Since its development in 1977, the SJM valve has become the most used mechanical valve in Japan and throughout the world. Because of its excellent durability, the SJM valve is typically used for relatively young patients,1 and its high performance and low event rate during long follow-ups have been reported previously (Table).1–4 The long-term outcomes are of specific interest, and cardiac surgeons are especially interested in the rates of thromboembolism, bleeding, reoperation, valve-related deaths, and valve-related complications (pannus formation, paravalvular leakage with hemolysis, valve thrombosis, and prosthetic valve endocarditis). According to the Society of Thoracic Surgeons/American Association for Thoracic Surgery (STS/AATS) guidelines for reporting mortality and morbidity after cardiac valve interventions,5,6 these complications should be evaluated using standardized valve-specific criteria. In particular, thromboembolism and bleeding, which have rates of development that are constant over time, should be evaluated by not only the actual rates but also the linearized rates.